Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
AstraZeneca
Moodys
Colorcon
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Memantine Hydrochloride And Donepezil Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154635 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status Development Center for Biotechnology, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status Program Office, National Science & Technology, Biotechnology & Pharmaceuticals Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status Taipei Veterans General Hospital, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer’s Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Memantine Hydrochloride And Donepezil Hydrochloride

Condition Name

Condition Name for Memantine Hydrochloride And Donepezil Hydrochloride
Intervention Trials
Alzheimer's Disease 10
Dementia 2
Alzheimer Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Memantine Hydrochloride And Donepezil Hydrochloride
Intervention Trials
Alzheimer Disease 16
Dementia 4
Depression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Memantine Hydrochloride And Donepezil Hydrochloride

Trials by Country

Trials by Country for Memantine Hydrochloride And Donepezil Hydrochloride
Location Trials
United States 78
Spain 5
Canada 5
France 4
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Memantine Hydrochloride And Donepezil Hydrochloride
Location Trials
Florida 5
California 5
New York 5
North Carolina 5
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Memantine Hydrochloride And Donepezil Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Memantine Hydrochloride And Donepezil Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 4
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Memantine Hydrochloride And Donepezil Hydrochloride
Clinical Trial Phase Trials
Completed 10
Unknown status 5
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Memantine Hydrochloride And Donepezil Hydrochloride

Sponsor Name

Sponsor Name for Memantine Hydrochloride And Donepezil Hydrochloride
Sponsor Trials
Forest Laboratories 4
Johns Hopkins University 2
Program Office, National Science & Technology, Biotechnology & Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Memantine Hydrochloride And Donepezil Hydrochloride
Sponsor Trials
Other 22
Industry 14
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKinsey
Moodys
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.